Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma

Diseases of the Esophagus

Volumn 23, Issue 8, 2010, Pages 641-645

  Honda, M ^a   Miura, A ^a   Izumi, Y ^a   Kato, T ^a   Ryotokuji, T ^a   Monma, K ^b   Fujiwara, J ^b   Egashira, H ^b   Nemoto, T ^c  

^a Departments of Surgery   (Japan)

^b Departments of Endoscopy   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Chemotherapy; Doxorubicin; Esophageal squamous cell carcinoma; Metastasis

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DISTANT METASTASIS; DRUG EFFICACY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; FEMALE; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; LIVER METASTASIS; LUNG METASTASIS; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 78149410956     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2010.01070.x     Document Type: Article

References (32)

1. Ajani J A, Barthel J S, Bekaii-Saab T et al. Esophageal cancer. J Natl Compr Canc Netw 2008; 6: 818-49.
2. NCCN Clinical Practice Guidelines in Oncology: Esophageal Cancer V.L. 2009. Available from URL: .
3. Van Cutsem E, Moiseyenko V M, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-7.
4. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996-2004.
5. The Japanese Society for Esophageal Disease. Comprehensive Registry of Esophageal Cancer in Japan (1995-1997), 2nd edn., 2001.
6. Iizuka T, Kakegawa T, Ide H et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group trial. Jpn J Clin Oncol 1992; 22: 172-6.
7. Hayashi K, Ando N, Watanabe H et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001; 31: 419-23.
8. Nakamura T, Ide H, Eguchi R et al. Nedaplatin and 5-fluorouracil combined with radiotherapy for advanced esophageal cancer. Gan To Kagaku Ryoho 2003; 30: 803-7. (In Japanese.)
9. Honda M, Miura A, Kato T et al. Evaluation of combination chemotherapy with 5-FU, doxorubicin and CDDP in patients with advanced esophageal cancer. J Jpn Bronchoesophagol Soc 2008; 59: 539-44. (In Japanese.)
10. Kosugi S, Kanda T, Nakagawa S et al. Efficacy and toxicity of fluorouracil, doxorubicin, and cisplatin/nedaplatin treatment as neoadjuvant chemotherapy for advanced esophageal carcinoma. Scand J Gastroenterol 2005; 40: 886-92.
11. Tanaka T, Fujita H, Sueyoshi S et al. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy 2007; 53: 449-53.
12. Gisselbrecht C, Calvo F, Mignot L et al. Fluorouracil (F), adriamycin (A), and cisplatin (P) (FAP): combination chemotherapy of advanced esophageal carcinoma. Cancer 1983; 52: 974-7.
13. Eisenhauer E A, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
14. Japanese Society for Esophageal Disease. Guideline for Clinical and Pathologic Studies on Carcinoma of Esophagus, 9th edn. Esophagus, 2004; 1:61-88.
15. Siewert J R, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 2007; 17: 38-44.
16. Ezdinli E Z, Gelber R, Desai D V et al. Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 1980; 46: 2149-53.
17. Kelsen D P, Bains M, Cvitkovic E et al. Vindesine in the treatment of esophageal carcinoma: a phase II study. Cancer Treat Rep 1979; 63: 2019-21.
18. Engstrom P F, Lavin P T, Klaassen D J. Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. Cancer Treat Rep 1983; 67: 713-5.
19. Taguchi T, Wakui A, Nabeya K et al. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group. Jpn J Cancer Chemother 1992; 19: 483-8.
20. Conroy T, Etienne P L, Adenis A et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol 1996; 14: 164-70.
21. Muro K, Hamaguchi T, Ohtsu A et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004; 15: 955-9.
22. Bleiberg H, Conroy T, Paillot B et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997; 33: 1216-20.
23. Conroy T, Etienne P L, Adenis A et al. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol 2002; 13: 721-9.
24. Lee J, Im Y H, Cho E Y et al. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2008; 62: 77-84.
25. Airoldi M, Cortesina G, Giordano C et al. Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol 2003; 20: 19-24.
26. Yano M, Takachi K, Doki Y et al. Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus. Dis Esophagus 2006; 19: 158-63.
27. Kuwahara A, Yamamori M, Nishiguchi K et al. Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 2009; 28: 305-11.
28. Di Lauro L, Giacinti L, Arena M G et al. Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. J Exp Clin Cancer Res 2009; 28: 34.
29. Kulke M H, Wu B, Clark J W et al. A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus. Cancer Invest 2006; 24: 229-34.
30. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 3: 36-46.
31. Janmaat M L, Gallegos-Ruiz M I, Rodriguez J A et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006; 24: 1612-9.
32. Safran H, Suntharalingam M, Dipetrillo T et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 2008; 70: 391-5.